This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carteaux, J. P. Articles by Roux, S. Search for Related Content PubMed PubMed Citation Articles by Carteaux, J. P. Articles by Roux, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Thinners Hazardous Substances DB HEPARIN

(Circulation. 1995;91:1568-1574.)
© 1995 American Heart Association, Inc.

Articles

Activated Clotting Time as an Appropriate Test to Compare Heparin and Direct Thrombin Inhibitors Such as Hirudin or Ro 46-6240 in Experimental Arterial Thrombosis

Jean Pierre Carteaux, MD; Alain Gast, PhD; Thomas B. Tschopp, MD; Sébastien Roux, MD

From the Pharma Division (A.G., T.T., S.R.), F. Hoffmann-La Roche Ltd, Basel, Switzerland; and Service de Chirurgie Cardiaque et de Chirurgie Experimentale (J.P.C.), Nancy, France.

Correspondence to Dr Sébastien Roux, Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4002 Basel, Switzerland.

Background Specific thrombin inhibitors are considered to be more potent antithrombotics than heparin. However, the relation between the systemic anticoagulation generated by thrombin inhibitors and their antithrombotic effect is not well defined. In a guinea pig carotid thrombosis model, the activated clotting time (ACT), the activated partial thromboplastin time (aPTT), and thrombin-generation tests were evaluated for their ability to predict the arterial antithrombotic effect of direct thrombin inhibitors such as hirudin and Ro 46-6240 compared with heparin.

Methods and Results Thrombosis of the carotid artery was induced by subendothelial damage in guinea pigs, and the subsequent cyclic flow variations were monitored. The effects of pretreatment with intravenous heparin, hirudin, and Ro 46-6240 were tested. After doubling the baseline aPTT, 1 IU · kg^-1 · min^-1 heparin was inactive, whereas either hirudin or Ro 46-6240 (30 µg · kg^-1 · min^-1) prevented thrombus formation by 80%. Heparin (10 IU · kg^-1 · min^-1) induced the same antithrombotic effect but with indefinite aPTT prolongation. However, for similar prolongation of the ACT, the three compounds had equivalent antithrombotic effects. Thrombin generation was predictive of the antithrombotic effect of the thrombin inhibitors but not of heparin.

Conclusions The arterial antithrombotic effect of direct thrombin inhibitors, when compared with those of heparin, should be evaluated by the ACT and not the aPTT or thrombin-generation assays. For a "therapeutic" aPTT prolongation, thrombin inhibitors induce higher systemic anticoagulation than does heparin and thus might unduly have higher bleeding liability.

Key Words: anticoagulants • coagulation • heparin • thrombosis • hemostasis

This article has been cited by other articles:

				R. F Baugh Platelets and whole blood coagulation Perfusion, January 1, 2000; 15(1): 41 - 50. [Abstract] [PDF]

				R. J. Leadley Jr, C. J. Kasiewski, J. S. Bostwick, R. Bentley, C. T. Dunwiddie, and M. H. Perrone Inhibition of Repetitive Thrombus Formation in the Stenosed Canine Coronary Artery by Enoxaparin, But Not by Unfractionated Heparin Arterioscler Thromb Vasc Biol, June 1, 1998; 18(6): 908 - 914. [Abstract] [Full Text] [PDF]

				D. Pratico, N. P. Murphy, and D. J. Fitzgerald J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1178 - 1185. [Abstract] [Full Text]